A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

I5B-MC-JGDM -

The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Sarcoma
What the trial is testing?
Doxorubicin, Olaratumab
Could I receive a Placebo?
No
Enrollment Goal
51
Trial Dates
Oct 11, 2016 - Jul 5, 2018
How long will I be in the trial?
Your participation could last up to 25 weeks depending on how you and your tumor respond.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.